Literature DB >> 16435179

Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up.

L J W M Pierik1, F J van Spronsen, C M A Bijleveld, C M L van Dael.   

Abstract

Hereditary tyrosinaemia type I is an autosomal recessive inborn error of tyrosine catabolism caused by a deficiency of the enzyme fumarylacetoacetase that results in liver failure, hepatocellular carcinoma, renal tubular dysfunction and acute intermittent porphyria. When treated with liver transplantation, tyrosinaemia type I was considered to be cured. Some years after the first liver transplantations in these patients, some reports focused on the renal function after transplantation. These reports showed that urinary succinylacetone excretion remained but that tubular function normalized. In this report we discuss the long-term renal follow-up (mean follow-up time 11 years, range 7-14 years) after liver transplantation in 9 patients with tyrosinaemia type I treated by liver transplantation in our centre. An evaluation was made of renal function and succinylacetone excretion in urine. In all patients we found a persistent excretion of succinylacetone in the urine. With respect to the glomerular function, we can conclude that there is no clear change in GFR. At the same time, tubulopathy persisted in some patients. We consider that excretion of metabolites such as succinylacetone will be an important contributing factor to tubular dysfunction after liver transplantation in patients with tyrosinaemia type I. Therefore, notwithstanding the major effect of liver transplantation on tyrosine metabolism, renal tubular dysfunction remains at risk and needs careful monitoring. Progressive tubular dysfunction can cause glomerular damage. The use of low-dose NTBC might be considered after liver transplantation in case of tubulopathy to prevent progression of tubular and glomerular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16435179     DOI: 10.1007/s10545-005-0059-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  23 in total

1.  Liver transplantation for hereditary tyrosinemia--early transplantation following the patient's stabilization.

Authors:  E M Sokal; R Bustos; F Van Hoof; J B Otte
Journal:  Transplantation       Date:  1992-11       Impact factor: 4.939

2.  Homotransplantation of the liver in a patient with hepatoma and hereditary tyrosinemia.

Authors:  R O Fisch; E R McCabe; D Doeden; L J Koep; J G Kohlhoff; A Silverman; T E Starzl
Journal:  J Pediatr       Date:  1978-10       Impact factor: 4.406

Review 3.  Tyrosinemia: the Quebec experience.

Authors:  K Paradis
Journal:  Clin Invest Med       Date:  1996-10       Impact factor: 0.825

4.  Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation.

Authors:  F J van Spronsen; G P Smit; F A Wijburg; Y Thomasse; G Visser; H S Heymans
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

5.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

Review 6.  From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.

Authors:  E A Lock; M K Ellis; P Gaskin; M Robinson; T R Auton; W M Provan; L L Smith; M P Prisbylla; L C Mutter; D L Lee
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

7.  The effects of early treatment of hereditary tyrosinemia type I in infancy by orthotopic liver transplantation.

Authors:  M W Flye; C A Riely; B E Hainline; S Sassa; R J Gusberg; K J Blakemore; K W Barwick; A L Horwich
Journal:  Transplantation       Date:  1990-05       Impact factor: 4.939

8.  Rapid improvement in the renal tubular dysfunction associated with tyrosinemia following hepatic replacement.

Authors:  L R Shoemaker; C F Strife; W F Balistreri; F C Ryckman
Journal:  Pediatrics       Date:  1992-02       Impact factor: 7.124

9.  Renal failure in adult patients with hereditary tyrosinaemia type I.

Authors:  E A Kvittingen; T Talseth; S Halvorsen; C Jakobs; T Hovig; A Flatmark
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

Review 10.  Tyrosinaemia--treatment and outcome.

Authors:  E A Kvittingen
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

View more
  8 in total

1.  Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice.

Authors:  Silvia Espejel; Garrett R Roll; K John McLaughlin; Andrew Y Lee; Jenny Y Zhang; Diana J Laird; Keisuke Okita; Shinya Yamanaka; Holger Willenbring
Journal:  J Clin Invest       Date:  2010-08-25       Impact factor: 14.808

2.  Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.

Authors:  Víctor R De Jesús; Barbara W Adam; Daniel Mandel; Carla D Cuthbert; Dietrich Matern
Journal:  Mol Genet Metab       Date:  2014-07-17       Impact factor: 4.797

Review 3.  Liver transplantation for pediatric inherited metabolic disorders: Considerations for indications, complications, and perioperative management.

Authors:  Kimihiko Oishi; Ronen Arnon; Melissa P Wasserstein; George A Diaz
Journal:  Pediatr Transplant       Date:  2016-06-21

Review 4.  The Kidney in Pediatric Liver Disease.

Authors:  Robyn Greenfield Matloff; Ronen Arnon
Journal:  Curr Gastroenterol Rep       Date:  2015-09

5.  Cost-Consequence Analysis of Nitisinone for Treatment of Tyrosinemia Type I.

Authors:  Mariève Simoncelli; Johanne Samson; Jean-François Bussières; Jacques Lacroix; Marc Dorais; Renaldo Battista; Sylvie Perreault
Journal:  Can J Hosp Pharm       Date:  2015 May-Jun

6.  Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.

Authors:  David C Bartlett; Mary Anne Preece; Elisabeth Holme; Carla Lloyd; Phil N Newsome; Patrick J McKiernan
Journal:  J Inherit Metab Dis       Date:  2012-03-29       Impact factor: 4.982

7.  Renal tubular function in children with tyrosinaemia type I treated with nitisinone.

Authors:  S Santra; M A Preece; S-A Hulton; P J McKiernan
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.750

8.  Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.

Authors:  Sebene Mayorandan; Uta Meyer; Gülden Gokcay; Nuria Garcia Segarra; Hélène Ogier de Baulny; Francjan van Spronsen; Jiri Zeman; Corinne de Laet; Ute Spiekerkoetter; Eva Thimm; Arianna Maiorana; Carlo Dionisi-Vici; Dorothea Moeslinger; Michaela Brunner-Krainz; Amelie Sophia Lotz-Havla; José Angel Cocho de Juan; Maria Luz Couce Pico; René Santer; Sabine Scholl-Bürgi; Hanna Mandel; Yngve Thomas Bliksrud; Peter Freisinger; Luis Jose Aldamiz-Echevarria; Michel Hochuli; Matthias Gautschi; Jessica Endig; Jens Jordan; Patrick McKiernan; Stefanie Ernst; Susanne Morlot; Arndt Vogel; Johannes Sander; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-08-01       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.